Nosa Plugs
Nosa Plugs AB is a Swedish listed group built around patented slow-release technology that incorporates substances into plastic products. Through its subsidiaries, the company develops, markets and distributes niche consumer and healthcare products, including intranasal and odor-control offerings, in Europe and the United States.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueProducts such as Nozoil and related nasal-care offerings sold through pharmacy and other channels.
Products designed to reduce or manage odor-related issues for consumer and healthcare use.
Products positioned for hygiene and microbial management applications.
Products and programs intended to support olfactory rehabilitation and training.
Proprietary intranasal delivery technology used to enable new product development and licensing opportunities.
Customers
Nosa sells through both B2B and B2C channels, with pharmacies, wholesalers, distributors and healthcare buyers forming the core commercial base. End customers include consumers seeking nasal-care and odor-control products, as well as healthcare and institutional users that buy through pharmacy and distribution networks.
They buy Nozoil and consumer health products for retail and online pharmacy sales.
They distribute NOSA products into national pharmacy networks and extend market access.
They purchase nasal-care, odor-control and smell-training products for personal use.
They buy selected products for clinical or institutional use through procurement channels.
They buy or resell products to build country-level coverage and market entry.
Strategy
Nosa’s strategy is to combine internal product development with selective acquisition of niche brands and products that can be scaled through shared sales and distribution channels. The company also focuses on expanding pharmacy distribution in Europe and validating its intranasal technology platform for future product development.
Pharmacy access is central to reaching consumers efficiently and building recurring product sales.
The patented slow-release platform underpins future product innovation and potential licensing value.
Acquisitions can add products that fit existing channels and improve commercial leverage.
Geography
The group reports sales primarily in Europe and the United States, with operations structured around selected country launches and distribution partnerships. Its commercial footprint is therefore shaped by pharmacy-channel access, local wholesaler relationships and regulatory requirements in each market.
Risks
The business depends on distributors, suppliers and patent protection, so commercial execution and intellectual-property protection are central risks. As a small product company with international sales, it is also exposed to currency swings, regulatory requirements, raw-material availability and the need for ongoing financing.
- Distribution dependenceImpact: HighLikelihood: Medium
The company relies on wholesalers, pharmacies and channel partners to reach end customers.
Exposure: Europe and North America sales channels
- Patent and IP protectionImpact: HighLikelihood: Medium
Products and the platform are based on proprietary technology that may be difficult to fully protect.
Exposure: New products and drug-delivery platform
- Financing and liquidity needsImpact: HighLikelihood: Low
Product development and commercialization can require external funding before scale is reached.
Exposure: Group-level cash flow
- Supplier and raw-material dependenceImpact: MediumLikelihood: Medium
Manufacturing and packaging require reliable third-party inputs and logistics.
Exposure: Product supply chain
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
International sales and costs create currency exposure across markets.
Exposure
Accounting
Judgemental itemsGoodwill from acquisitions must be assessed against the cash-generating unit and can be written down if expected benefits weaken.
Impact: Could materially affect equity and operating results
Business combinations require fair-value allocation of assets and liabilities, which affects goodwill and future amortization.
Impact: Affects reported asset base and earnings profile
Outstanding option programs can dilute existing shareholders and require disclosure of potential share capital changes.
Impact: Affects equity and per-share analysis
Parent-company service revenue is eliminated in consolidation, so standalone parent figures do not reflect group revenue.
Impact: Important for understanding consolidated revenue
Similar listed companies
Publicly listed companies with a comparable business focus.
Nasus Pharma Ltd
NSRX · Pharmaceutical Preparations
Nasus Pharma Ltd is a clinical-stage pharmaceutical company focused on developing innovative intranasal drug products.
Sedana Medical
SEDANA · Health Care
Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals.
Essity B
ESSITY-B · Consumer Staples
Essity Aktiebolag (publ) is a global hygiene and health company that develops, produces, and sells personal care and tissue products.
Essity A
ESSITY-B · Consumer Staples
Essity Aktiebolag is a global hygiene and health company headquartered in Sweden.
Polyrizon Ltd.
PLRZ · Surgical & Medical Instruments & Apparatus
Cinclus Pharma Holding
CINPHA · Health Care
Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD).
Last updated: 24/09/2026